For the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one of more risk factors, the therapeutic value of apixaban is comparable with that of dabigatran.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.